Direct Oral Anticoagulants Utilization and Expenditure in the Pharmacy Segment During the COVID-19 Pandemic in Russia

Abstract

BACKGROUND: The analysis of direct oral anticoagulants use in outpatients with coronavirus infection and their utilization in the pharmacy segment is an essential task of modern healthcare.

AIM: This work aimed to analyze the outpatient utilization of direct oral anticoagulants in the pharmacy segment of the Russian pharmaceutical market during the COVID-19 pandemic based on the national guidelines.

MATERIAL AND METHODS: We calculated the utilization of direct oral anticoagulants (rivaroxaban and apixaban) at defined daily doses in all registered outpatients with COVID-19 in the pharmacy segment of the pharmaceutical market (24,343,383 people). This was done by determining the total utilization of these drugs each year of the pandemic (2020–2023) in Russia and dividing the obtained value by the defined daily dose recommended by the World Health Organization. Then we compared the results with the course doses recommended in the Russian guidelines issued in 2020–2023 for direct oral anticoagulants use in patients with COVID-19.

RESULTS: In 2020, the hypothetical utilization of apixaban and rivaroxaban by outpatients with COVID-19 in Russia in 2020 was 76.6 defined daily doses per patient. In 2021, apixaban utilization decreased to values comparable to the recommended doses (21.1 defined daily doses), while rivaroxaban utilization was 10.6. In 2022, the defined daily doses for apixaban and rivaroxaban were 9.2 and 4.2, respectively.

CONCLUSION: In 2020, the utilization of direct oral anticoagulants (apixaban and rivaroxaban) in outpatients with COVID-19 exceeded Russian guideline-recommended dosing regimens by more than fivefold, with a downward trend in the following pandemic years.

Keywords

COVID-19 / direct oral anticoagulants / pharmacoepidemiological studies / outpatients / guidelines

References

[1] Liao SC, Shao SC, Chen YT, et al. Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and meta-analysis. Crit Care. 2020;24(1):464. doi: 10.1186/s13054-020-03175-z EDN: IRHXIC

[2] Davtyan PA, Gumerov RM, Zagidullin ShZ, et al. Is anticoagulant therapy necessary after hospitalization with covid-19 pneumonia? Russian Journal of Cardiology. 2021;26(4S):53–58. doi: 10.15829/1560-4071-2021-4652 EDN: VRMOSK

[3] Drapkina OM, Drozdova LY, Avdeev SN, et al The outpatient medical care in patients with chronic diseases under dispensary supervision in the conditions of the COVID-19 pandemic. Temporary guidelines. Version 2. Cardiovascular Therapy and Prevention. 2021;20(8):245–290. doi: 10.15829/1728-8800-2021-3172 EDN: SRCERD

[4] Livzan MA, Drapkina OM, Nikolaev NA, et al. Algorithms for adult outpatient care of coronavirus disease 2019 (COVID-19) and its assumption. Cardiovascular Therapy and Prevention. 2021;20(4):42–51. doi: 10.15829/1728-8800-2021-2916 EDN: XERRQA

[5] Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–1026. doi: 10.1111/jth.14810 EDN: OLOAHQ

[6] Flumignan RL, Civile VT, Tinôco JDS, et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2022;3(3):CD013739. doi: 10.1002/14651858.CD013739.pub2 EDN: FGGTAY

[7] Santos BC, Flumignan RL, Civile VT, et al Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database Syst Rev. 2023;8(8):CD015102. doi: 10.1002/14651858.CD015102.pub2 EDN: MIODBZ

[8] Hernandez I, Tadrous M, Magnani JW, et al. Impact of the COVID-19 pandemic on global anticoagulant sales: a cross-sectional analysis across 39 countries. Am J Cardiovasc Drugs. 2021;21(5):581–583. doi: 10.1007/s40256-021-00475-9 EDN: TDJQNQ

[9] Baybulatova EA, Chenkurov MS, Korovyakova EA, et al. Direct oral anticoagulants' consumption and expenditure in the COVID-19 pandemic in Russia and clinical practice guidelines for their use. Pharmacoepidemiology. 2024;3(1):1–32. doi: 10.3390/pharma3010001 EDN: IWIHDU

[10] Aynabekova B, Baev V, Vasiliev S, et al. Recommendations for the outpatient management of covid-19 patients with the acute infection and post-COVID syndrome (issued by the Moscow city scientific society of physicians, Moscow, 2021) prof. Pavel A. Vorobiev, editor. Problems of Standardization in Healthcare. 2021;(7–8):3–96. doi: 10.26347/1607-2502202107-08003-096 EDN: CJNPYU

[11] Zabolotskikh IB, Kirov MYu, Lebedinskii KM, et al. Anesthesia and intensive care for patients with COVID-19. Russian federation of anesthesiologists and reanimatologists guidelines. Annals of critical care. 2020;(S1):9–120. doi: 10.21320/1818-474X-2020-S1-9-120 EDN: BVMRHN

[12] Shlyakhto EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):129–148. doi: 10.15829/1560-4071-2020-3-3801 EDN: NTALPB

[13] Geng Y, Meng C, Gao T, et al. The efficacy and safety of out-hospital anticoagulation therapy with direct oral anticoagulant for COVID-19. Eur J Intern Med. 2023;115:160–163. doi: 10.1016/j.ejim.2023.06.023 EDN: BJFYEM

[14] Dawwas GK, Leonard CE, Lewis JD, Cuker A. Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data. Ann Intern Med. 2022;175(1):20–28. doi: 10.7326/M21-0717 EDN: UEGCYU

[15] Buckley BJR, Lane DA, Calvert P, et al. Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: a systematic review and meta-analysis. J Clin Med. 2022;11(13):3788. doi: 10.3390/jcm11133788 EDN: GEGBOK

[16] Diagnosis and treatment of atrial fibrillation Recommendations of the All-Russian society of cardiologists and the All-Russian society of cardiologists, 2011. Rational pharmacotherapy in cardiology. 2011;7(4 (S)):1–78. (In Russ.) Available from: https://cyberleninka.ru/article/n/diagnostika-i-lechenie-fibrillyatsii-predserdiy-rekomendatsii-vnok-i-vnoa-2011-g Accessed: 07.03.2025.

Funding

Российский университет дружбы народов им. П. Лумумбы (исследовательский грант) №0321040000RUDN 0321040000

RIGHTS & PERMISSIONS

Eco-Vector